Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.
Journal: The Journal of clinical investigation
Published: July 07, 2026
Molecular characterization of NSMP endometrial cancer and its relevance for treatment.
Journal: Gynecologic oncology
Published: April 03, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.
Journal: Gynecologic oncology
Published: March 03, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.
Journal: bioRxiv : the preprint server for biology
Published: February 27, 2026
Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 14, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.
Journal: Nature communications
Published: November 05, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.
Journal: JCO precision oncology
Published: September 04, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Journal: JCO precision oncology
Published: August 27, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Journal: Nature communications
Published: July 12, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
Journal: Gynecologic oncology reports
Published: May 19, 2025
Last Updated: 09/26/2026